DK3338790T3 - Oligopeptid-forbindelser og anvendelser deraf - Google Patents

Oligopeptid-forbindelser og anvendelser deraf Download PDF

Info

Publication number
DK3338790T3
DK3338790T3 DK18155330.6T DK18155330T DK3338790T3 DK 3338790 T3 DK3338790 T3 DK 3338790T3 DK 18155330 T DK18155330 T DK 18155330T DK 3338790 T3 DK3338790 T3 DK 3338790T3
Authority
DK
Denmark
Prior art keywords
oligopeptime
compounds
oligopeptime compounds
Prior art date
Application number
DK18155330.6T
Other languages
English (en)
Inventor
Marit Otterlei
Per Arne Aas
Emadoldin Feyzi
Original Assignee
Apim Therapeutics As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apim Therapeutics As filed Critical Apim Therapeutics As
Application granted granted Critical
Publication of DK3338790T3 publication Critical patent/DK3338790T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/03—Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; catalysing transmembrane movement of substances (3.6.3)
    • C12Y306/03044—Xenobiotic-transporting ATPase (3.6.3.44)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
DK18155330.6T 2008-02-22 2009-02-20 Oligopeptid-forbindelser og anvendelser deraf DK3338790T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0803352.4A GB0803352D0 (en) 2008-02-22 2008-02-22 Oligopeptidic compounds and uses thereof
US10058408P 2008-09-26 2008-09-26
EP09713402.7A EP2254904B1 (en) 2008-02-22 2009-02-20 Oligopeptidic compounds and uses thereof

Publications (1)

Publication Number Publication Date
DK3338790T3 true DK3338790T3 (da) 2022-05-09

Family

ID=39284467

Family Applications (2)

Application Number Title Priority Date Filing Date
DK18155330.6T DK3338790T3 (da) 2008-02-22 2009-02-20 Oligopeptid-forbindelser og anvendelser deraf
DK09713402.7T DK2254904T3 (da) 2008-02-22 2009-02-20 Oligopeptid-forbindelser og anvendelser deraf

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK09713402.7T DK2254904T3 (da) 2008-02-22 2009-02-20 Oligopeptid-forbindelser og anvendelser deraf

Country Status (23)

Country Link
US (3) US8871724B2 (da)
EP (2) EP2254904B1 (da)
JP (2) JP5863240B2 (da)
KR (3) KR101653774B1 (da)
CN (1) CN102015758B (da)
AU (1) AU2009216567B2 (da)
BR (1) BRPI0908853B1 (da)
CA (1) CA2715940C (da)
DK (2) DK3338790T3 (da)
ES (2) ES2670334T3 (da)
GB (1) GB0803352D0 (da)
HR (3) HRP20220585T3 (da)
HU (2) HUE059174T2 (da)
IL (1) IL207384B (da)
LT (2) LT3338790T (da)
MX (1) MX2010008989A (da)
NO (1) NO2254904T3 (da)
PL (2) PL2254904T3 (da)
PT (2) PT2254904T (da)
RU (1) RU2549675C2 (da)
TR (1) TR201807218T4 (da)
WO (1) WO2009104001A2 (da)
ZA (2) ZA201005506B (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0803352D0 (en) * 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
GB201001602D0 (en) * 2010-02-01 2010-03-17 Cytovation As Oligopeptidic compounds and uses therof
JP2013522169A (ja) * 2010-02-24 2013-06-13 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 炎症および好中球減少症の処置のための化合物
CA2890658A1 (en) 2012-11-09 2014-05-15 The Johns Hopkins University A genetic assay to determine prognosis in polycythemia vera patients
WO2014126965A2 (en) 2013-02-13 2014-08-21 Yale University Compositions and methods for treating pathological calcification and ossification
CN104558119B (zh) * 2013-10-17 2019-03-08 上海宝恒泓康生物技术有限公司 Yap蛋白抑制多肽及其应用
GB201319621D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Antimicrobial agents and their use in therapy
GB201319620D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Immunosuppressive agents and their use in therapy
CN106459168B (zh) * 2014-04-02 2020-03-24 马歇尔大学科研协会 强心性类固醇拮抗剂和相关方法
WO2016058547A1 (zh) 2014-10-17 2016-04-21 上海宝恒泓康生物技术有限公司 高活性的肿瘤抑制剂及其制法和应用
GB201507722D0 (en) 2015-05-06 2015-06-17 Norwegian Univ Sci & Tech Ntnu Anti-bacterial agents and their use in therapy
GB201507721D0 (en) * 2015-05-06 2015-06-17 Norwegian Univ Sci & Tech Ntnu Immunosuppressive agents and their use in therapy
AU2016264364B2 (en) 2015-05-19 2022-06-23 Yale University Compositions for treating pathological calcification conditions, and methods using same
JP2019532915A (ja) 2016-08-05 2019-11-14 イエール ユニバーシティ 小児鎌状赤血球貧血患者における脳卒中予防のための組成物および方法
IL254361A0 (en) * 2017-09-06 2017-11-30 Nat Inst Biotechnology Negev Ltd Compounds to suppress the methyltransferase setd6
GB202006699D0 (en) 2020-05-06 2020-06-17 Therapim Pty Ltd Dosage regimen
KR102483938B1 (ko) * 2020-06-12 2023-01-04 (주)케어젠 펜타펩타이드를 유효성분으로 포함하는 항알러지 또는 아토피피부염 개선용 조성물
CN112813042B (zh) * 2021-02-08 2021-08-27 南京市妇幼保健院 乳腺脂肪组织来源的多肽及其抗肿瘤应用
WO2024011300A1 (en) * 2022-07-13 2024-01-18 L'oreal Modified peptides, composition, method for inhibiting contraction of muscle cells, method for improving the skin and use of a modified peptide

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69034085T2 (de) 1989-04-10 2004-05-27 Helix BioMedix, Inc., Bothell Lytsche und proliferative Peptide und deren Verwendung als Pharmaka und Phytopharmaka
EP0497867A1 (en) * 1989-10-23 1992-08-12 Schering Corporation Polypeptide inhibitors of gamma interferon
US5888762A (en) 1990-06-05 1999-03-30 Centre National De La Recherche Scientifique (Cnrs) Neurotropic growth factors comprising a homeobox peptide
FR2662698A1 (fr) 1990-06-05 1991-12-06 Centre Nat Rech Scient Nouveaux facteurs de croissance neurotropes comprenant un peptide homeoboite.
EP0610254B1 (en) 1991-09-20 2004-09-01 Amgen Inc. Glial derived neurotrophic factor
US5534110A (en) 1993-07-30 1996-07-09 Lam Research Corporation Shadow clamp
DE69433848T2 (de) 1993-10-05 2005-05-25 Xoma Technology Ltd., Berkeley Bpi-protein-produkte für definierte funktionen des reticuloendothelialen systems
GB9422175D0 (en) 1994-11-03 1994-12-21 Univ Dundee Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof
GB9509557D0 (en) * 1995-05-11 1995-07-05 Univ Dundee PCNA binding substance
FR2739621B1 (fr) 1995-10-05 1997-12-05 Centre Nat Rech Scient Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives
DE69838478T2 (de) 1997-03-14 2008-06-26 Crusade Laboratories Ltd. Verfahren zur Erkennung von Regulatoren des Zellzyklus
WO1999029721A1 (en) 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
TWI227136B (en) 1998-05-21 2005-02-01 Smithkline Beecham Corp Novel pharmaceutical composition for the prevention and/or treatment of cancer
US6368831B1 (en) 1998-06-29 2002-04-09 Childrens Hospital Los Angeles Treatment of hyperproliferative disorders
US6352844B1 (en) 1998-06-29 2002-03-05 Childrens Hospital Los Angeles Treatment of hyperproliferative disorders
GB9814527D0 (en) * 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
US6127177A (en) 1998-09-11 2000-10-03 Massachusetts Institute Of Technology Controlled reversible poration for preservation of biological materials
ATE419273T1 (de) 1998-11-13 2009-01-15 Cyclacel Ltd Translokationsvektoren abgeleitet von der antennapedia homeodomain helix 3
WO2000075184A1 (en) 1999-06-04 2000-12-14 Yale University Modulation of protein levels using the scf complex
US6696263B1 (en) 1999-09-23 2004-02-24 Rigel Pharmaceuticals, Inc. PCNA associated cell cycle proteins, compositions and methods of use
CN1297923A (zh) * 1999-11-29 2001-06-06 上海博容基因开发有限公司 一种新的多肽——人含细胞色素c结构域的脂蛋白105和编码这种多肽的多核苷酸
GB9928323D0 (en) 1999-11-30 2000-01-26 Cyclacel Ltd Peptides
WO2001055309A2 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU2001238347A1 (en) * 2000-02-28 2001-09-12 Hyseq, Inc. Novel nucleic acids and polypeptides
JP4503801B2 (ja) * 2000-09-08 2010-07-14 独立行政法人科学技術振興機構 新規ヒト癌・精巣抗原及びその遺伝子
US6627401B2 (en) * 2000-12-28 2003-09-30 Council Of Scientific And Industrial Research Method for detecting a single nucleotide polymorphism in p21waf1/cip1 gene as an indicator of risk of esophageal cancer
WO2002079408A2 (en) 2001-03-28 2002-10-10 Helix Biomedix, Inc. Short bioactive peptides and methods for their use
US6875744B2 (en) 2001-03-28 2005-04-05 Helix Biomedix, Inc. Short bioactive peptides
US20030114362A1 (en) 2001-06-08 2003-06-19 Novaspin Biotech Gmbh Penta-or tetrapeptide binding to somatostatin receptors and the use of the same
WO2003042239A1 (en) * 2001-11-12 2003-05-22 Stichting Sanquin Bloedvoorziening Peptides inhibiting signaling by ras-like gtpases
AU2002366364A1 (en) 2001-12-18 2003-06-30 Sloan-Kettering Institute For Cancer Research E2f and cancer therapy
US7517857B2 (en) 2002-01-29 2009-04-14 Posco Immune-modulating peptide
AU2003213700A1 (en) 2002-03-01 2003-09-16 Applied Immune Technologies Immunogens for treatment of neoplastic and infectious disease
EP1532164B1 (en) * 2002-08-20 2012-09-26 Polyphor Ltd. Template-fixed peptidomimetics with antibacterial activity
WO2004035732A2 (en) * 2002-08-29 2004-04-29 Five Prime Therapeutics, Inc. Human polypeptides encoded by polynucleotides and methods of their use
JP2006501820A (ja) * 2002-09-06 2006-01-19 バイエル・フアーマシユーチカルズ・コーポレーシヨン 修飾ｇｌｐ−１受容体アゴニストおよびそれらの薬理学的使用法
ATE378592T1 (de) * 2002-10-02 2007-11-15 Theraptosis S A Verfahren zum screening für modulatoren von mitochondrialer funktion
FR2849603B1 (fr) 2003-01-07 2006-09-08 Centre Nat Rech Scient Composition pour le transport intracellulaire de macromolecules ou particules biologiques
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
FR2855178B1 (fr) 2003-05-20 2005-08-05 Centre Nat Rech Scient Peptides modulateurs de l'activite du facteur de transcription engrailed
WO2005074521A2 (en) * 2004-01-30 2005-08-18 The Trustees Of Columbia University In The City Of New York C-TERMINAL p53 PALINDROMIC PEPTIDE THAT INDUCES APOPTOSIS OF CELLS WITH ABERRANT p53 AND USES THEREOF
AU2005241009A1 (en) * 2004-04-21 2005-11-17 Mcmaster University Myosin light chain kinase inhibitors and their use
GB0410498D0 (en) 2004-05-11 2004-06-16 Cyclacel Ltd Crystal
WO2006005042A2 (en) * 2004-06-30 2006-01-12 Cemines, Inc. Methods and compositions for the diagnosis,prognosis,and treatment of cancer
HUE038099T2 (hu) * 2004-12-21 2018-09-28 Musc Found For Res Dev Kompozíciók és módszerek sebgyógyulás és szöveti regeneráció elõsegítésére
IN2005CH00851A (da) * 2005-07-04 2008-01-25
WO2007019532A2 (en) 2005-08-04 2007-02-15 North Carolina State University Peptide aptamers that bind to the rep proteins of ssdna viruses
US20090286724A1 (en) * 2005-10-26 2009-11-19 Chugai Seiyaku Kabushiki Kaisha Aggregable glp-1 analogue and sustained-release pharmaceutical composition
EA200801847A1 (ru) 2006-02-17 2009-02-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн ПЕПТИДНОЕ ИНГИБИРОВАНИЕ ВЗАИМОДЕЙСТВИЯ caPCNA ПРИ РАКЕ
CU23511B6 (es) 2006-02-28 2010-04-13 Biorec B V Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas
EP2041283B1 (en) 2006-06-26 2013-02-20 The University Of British Columbia Secreted protein acidic and rich in cysteine (sparc) as chemotherapeutic sensitizers
JP5490714B2 (ja) 2007-11-28 2014-05-14 メディミューン，エルエルシー タンパク質製剤
GB0803352D0 (en) * 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof

Also Published As

Publication number Publication date
TR201807218T4 (tr) 2018-06-21
HUE037737T2 (hu) 2018-09-28
GB0803352D0 (en) 2008-04-02
KR101653774B1 (ko) 2016-09-05
ZA201105685B (en) 2012-05-25
JP6116614B2 (ja) 2017-04-19
AU2009216567A1 (en) 2009-08-27
WO2009104001A3 (en) 2010-04-15
HRP20220585T3 (hr) 2022-08-19
KR20100123728A (ko) 2010-11-24
NO2254904T3 (da) 2018-09-08
US9676822B2 (en) 2017-06-13
JP5863240B2 (ja) 2016-02-16
LT2254904T (lt) 2018-06-11
US20150017232A1 (en) 2015-01-15
KR101758671B1 (ko) 2017-07-17
PL3338790T3 (pl) 2022-07-11
RU2010134786A (ru) 2012-03-27
JP2015180634A (ja) 2015-10-15
EP2254904A2 (en) 2010-12-01
KR20160038903A (ko) 2016-04-07
IL207384A0 (en) 2010-12-30
CA2715940A1 (en) 2009-08-27
US8871724B2 (en) 2014-10-28
HRP20220585T1 (da) 2022-08-19
EP2254904B1 (en) 2018-04-11
CN102015758B (zh) 2017-04-12
ES2912122T3 (es) 2022-05-24
KR20170018485A (ko) 2017-02-17
EP3338790A3 (en) 2018-07-11
MX2010008989A (es) 2010-12-07
US20110020437A1 (en) 2011-01-27
PL2254904T3 (pl) 2018-08-31
LT3338790T (lt) 2022-05-25
CN102015758A (zh) 2011-04-13
KR101749204B1 (ko) 2017-06-20
HUE059174T2 (hu) 2022-10-28
WO2009104001A2 (en) 2009-08-27
JP2011512150A (ja) 2011-04-21
BRPI0908853B1 (pt) 2021-05-25
CA2715940C (en) 2020-06-30
PT2254904T (pt) 2018-06-04
AU2009216567B2 (en) 2013-11-07
IL207384B (en) 2018-05-31
US10213483B2 (en) 2019-02-26
RU2549675C2 (ru) 2015-04-27
EP3338790A2 (en) 2018-06-27
DK2254904T3 (da) 2018-06-06
BRPI0908853A2 (pt) 2017-05-30
ES2670334T3 (es) 2018-05-30
HRP20180718T1 (hr) 2018-07-13
ZA201005506B (en) 2011-10-26
EP3338790B1 (en) 2022-04-13
PT3338790T (pt) 2022-05-11
US20170246248A1 (en) 2017-08-31

Similar Documents

Publication Publication Date Title
DK3338790T3 (da) Oligopeptid-forbindelser og anvendelser deraf
BRPI0907231A2 (pt) pirrolpirimidinas e pirrolpiridinas
BRPI0821573A2 (pt) benzofuropirimidonas
ATE501136T1 (de) Imidazopyridinone
DK2170827T3 (da) Indolin-2-oner og aza-indolin-2-oner
ATE514696T1 (de) Diphenyl-dihydro-imidazopyridinone
DE602008002772D1 (de) Polyvinylpyrrolidonpulverzusammensetzungen
DE112008003636A5 (de) Mehrzuggruppierer
DE502007001207D1 (de) Elektrosaugkopf
BRPI0814519A2 (pt) Organopolissiloxano
BRPI0811451A2 (pt) Exopolissacarídeo
DE602008000923D1 (de) Einzelwaferätzgerät
DE602008000749D1 (de) Buschschneider
BRPI0812840A2 (pt) 2-imidazolinas
BRPI0815547A2 (pt) Depsipeptídeos cícliocos
AT505058A3 (de) Türschliesssystem
DE602008004695D1 (de) Katalysatorträgerwabe
BRPI0812994A2 (pt) Microbiocidas
DE602008001234D1 (de) Bandmaterialzuführvorrichtung
DE112008001216A5 (de) Magnetronplasmaanlage
DK2334596T3 (da) Ferriphosphatbaseret sammensætning og anvendelse heraf
DE502008001694D1 (de) Mitfahrhubwagen
BRPI0816288A2 (pt) Processos e compostos
DE602008001674D1 (de) Wimpernwickler
DE112008003094A5 (de) Geomatte